International Stem Cell Corporation (OTCBB: ISCO) www.internationalstemcell.com
announced that scientists in its wholly-owned subsidiary, Lifeline Cell
Technology (LCT), have developed a technology to modify human stem cells
by using engineered proteins, called "transducible transcription
factors" or "TTFs." TTFs are designed to pass into stem cells and direct
the stem cells to change into specific cell types that can be both
therapeutically-useful and can be used as revenue-generating research
products.
In contrast to more traditional cell therapy methods this technology
does not require the use of viruses or chemicals, and has the potential
to produce safe therapeutic cells from stem cells. In addition, the TTF
proteins are naturally eliminated by the cells when no longer required,
a characteristic that further improves safety. The Company intends that
this technology, once perfected, will first be used to create
revenue-generating research products for sale through Lifeline Cell
Technology's international distribution channels to the academic,
biotechnology and pharmaceutical markets for cellular proteins,
including the quickly growing markets for the study of stem cell biology
and drug testing.
According to Jeffrey Janus, Lifeline Cell Technology's CEO, "These
proteins can be sold into the market for cellular proteins which exceeds
$700 million and represents an excellent opportunity for LCT to grow
sales. Since the technology also has broad application in research and
therapy, it should provide ISCO with future out-licensing opportunities
to the biotechnology and pharmaceutical industries."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes
(eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of differing
genders, ages and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true stem
cell bank, UniStemCell™. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology (www.lifelinecelltech.com),
and stem cell-based skin care products through its subsidiary Lifeline
Skin Care (www.lifelineskincare.com).
More information is available at www.internationalstemcell.com
or follow us on Twitter @intlstemcell.
To receive ongoing corporate communications, please click on the
following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
Forward-looking Statements
Statements pertaining to anticipated developments, the potential
benefits of research programs and products, and other opportunities for
the company and its subsidiaries, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, regulatory approvals, need and
ability to obtain future capital, application of capital resources among
competing uses, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Dr. Simon Craw, Executive Vice
President Business Development
Phone: 760-940-6383
Email: ir@intlstemcell.com
or
Investor
Relations:
MZ Group
Mark McPartland
Phone: 212-301-7130
Email:
markmcp@mzgroup.us
Web: www.mz-ir.com